ALKERMES | ALKS - Spese Di Vendita E Di Amministrazione

Prezzo Delle Azioni
33.31
Cambio Giornaliero
-0.60 -1.77%
Mensile
13.42%
Annuale
19.65%
Q2 Previsione
32.32




Spese Di Vendita E Di Amministrazione Cambiamento Data
AbbVie USD 3.89B 325M 2025-12
Acadia Pharmaceuticals USD 146.73M 21.82M 2025-12
ALKERMES USD 187.2M 15.43M 2025-12
Amgen USD 1.94B 237M 2025-12
Biogen USD 545.2M 38.6M 2025-09
BioMarin Pharmaceutical USD 322.21M 98.79M 2025-12
Bristol-Myers Squibb USD 2.18B 392M 2025-12
Coherus Biosciences USD 15M 6.26M 2025-12
Eli Lilly USD 3.13B 391.3M 2025-12
Gilead Sciences USD 1.78B 425M 2025-12
Heron Therapeutics USD 23.74M 605K 2025-12
Ionis Pharmaceuticals USD 130M 43.43M 2025-12
J&J USD 6.03B 719M 2026-03
Malin Corporation EUR 1.1M 400K 2024-12
Merck USD 2.85B 215M 2025-12
Minerva Neurosciences USD 2.48M 58.79K 2024-09
Nektar Therapeutics USD 10.17M 10.17M 2025-12
Neurocrine Biosciences USD 301.8M 10.2M 2025-12
Otsuka Holdings JPY 278.3B 24.08B 2025-12
Ovoca Bio EUR 632K 2.33M 2025-06
Pfizer USD 4.08B 894M 2025-12
Regeneron Pharmaceuticals USD 775M 117.2M 2025-12
Vertex Pharmaceuticals USD 487M 41.9M 2025-12